HU206834B - Process for producing pharmaceutical compositions containing interferone and/or tumor necrosis factor for treating systhematically preneoplastic lesions - Google Patents
Process for producing pharmaceutical compositions containing interferone and/or tumor necrosis factor for treating systhematically preneoplastic lesions Download PDFInfo
- Publication number
- HU206834B HU206834B HU902145A HU214590A HU206834B HU 206834 B HU206834 B HU 206834B HU 902145 A HU902145 A HU 902145A HU 214590 A HU214590 A HU 214590A HU 206834 B HU206834 B HU 206834B
- Authority
- HU
- Hungary
- Prior art keywords
- tumor necrosis
- necrosis factor
- interferon
- priority
- combination
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 29
- 230000003902 lesion Effects 0.000 title claims abstract description 17
- 230000001855 preneoplastic effect Effects 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 102000003390 tumor necrosis factor Human genes 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 18
- 230000008569 process Effects 0.000 title claims description 9
- 102000014150 Interferons Human genes 0.000 claims abstract description 23
- 108010050904 Interferons Proteins 0.000 claims abstract description 23
- 229940079322 interferon Drugs 0.000 claims abstract description 22
- 230000009885 systemic effect Effects 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940044627 gamma-interferon Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 230000002925 chemical effect Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 14
- 108090000695 Cytokines Proteins 0.000 abstract description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000057041 human TNF Human genes 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000002341 thymus lymphoma Diseases 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3911720 | 1989-04-11 | ||
| DE4005416 | 1990-02-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU902145D0 HU902145D0 (en) | 1990-07-28 |
| HUT54303A HUT54303A (en) | 1991-02-28 |
| HU206834B true HU206834B (en) | 1993-01-28 |
Family
ID=25879777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU902145A HU206834B (en) | 1989-04-11 | 1990-04-10 | Process for producing pharmaceutical compositions containing interferone and/or tumor necrosis factor for treating systhematically preneoplastic lesions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5128126A (enExample) |
| EP (1) | EP0392300B1 (enExample) |
| JP (1) | JPH02304027A (enExample) |
| KR (1) | KR900015754A (enExample) |
| AT (1) | ATE79763T1 (enExample) |
| AU (1) | AU638982B2 (enExample) |
| CA (1) | CA2014130A1 (enExample) |
| DE (1) | DE59000270D1 (enExample) |
| DK (1) | DK0392300T3 (enExample) |
| ES (1) | ES2034790T3 (enExample) |
| GR (1) | GR3005528T3 (enExample) |
| HU (1) | HU206834B (enExample) |
| IE (1) | IE64765B1 (enExample) |
| IL (1) | IL94052A (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| WO1993011769A1 (fr) * | 1991-12-10 | 1993-06-24 | Otsuka Pharmaceutical Co., Ltd | Agent anticancereux |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5571797A (en) * | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
| WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| CN1527721A (zh) * | 2000-09-12 | 2004-09-08 | 基因特罗生物治疗公司 | 含治疗性蛋白混合物的组合物及其生产方法 |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| ATE541937T1 (de) * | 2001-04-06 | 2012-02-15 | Univ Chicago | Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| WO2005046746A2 (en) * | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| US20070212298A1 (en) * | 2004-08-25 | 2007-09-13 | Prefix Suffix | Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| CA2682050A1 (en) * | 2007-03-27 | 2008-10-02 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
| US20080241100A1 (en) * | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
| EP1977759A1 (en) * | 2007-03-27 | 2008-10-08 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9051882A (en) * | 1981-10-08 | 1983-04-27 | Berg, Kurt Frimann | Method and composition for treating a patient suffering from interferon-susceptible disorders |
| WO1983001198A1 (en) * | 1981-10-08 | 1983-04-14 | Kurt Frimann Berg | Method and composition for treating a patient suffering from interferon-susceptible disorder |
| DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
-
1990
- 1990-03-31 ES ES199090106221T patent/ES2034790T3/es not_active Expired - Lifetime
- 1990-03-31 DE DE9090106221T patent/DE59000270D1/de not_active Expired - Fee Related
- 1990-03-31 AT AT90106221T patent/ATE79763T1/de not_active IP Right Cessation
- 1990-03-31 EP EP90106221A patent/EP0392300B1/de not_active Expired - Lifetime
- 1990-03-31 DK DK90106221.6T patent/DK0392300T3/da active
- 1990-04-09 IL IL9405290A patent/IL94052A/en not_active IP Right Cessation
- 1990-04-09 CA CA002014130A patent/CA2014130A1/en not_active Abandoned
- 1990-04-09 US US07/505,269 patent/US5128126A/en not_active Expired - Fee Related
- 1990-04-10 AU AU53105/90A patent/AU638982B2/en not_active Ceased
- 1990-04-10 JP JP2094884A patent/JPH02304027A/ja active Pending
- 1990-04-10 HU HU902145A patent/HU206834B/hu not_active IP Right Cessation
- 1990-04-10 IE IE129790A patent/IE64765B1/en not_active IP Right Cessation
- 1990-04-11 KR KR1019900004955A patent/KR900015754A/ko not_active Ceased
-
1992
- 1992-08-27 GR GR920401805T patent/GR3005528T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02304027A (ja) | 1990-12-17 |
| AU638982B2 (en) | 1993-07-15 |
| DK0392300T3 (da) | 1992-09-28 |
| IE64765B1 (en) | 1995-09-06 |
| DE59000270D1 (de) | 1992-10-01 |
| IE901297L (en) | 1990-10-11 |
| GR3005528T3 (enExample) | 1993-06-07 |
| ES2034790T3 (es) | 1993-04-01 |
| CA2014130A1 (en) | 1990-10-11 |
| KR900015754A (ko) | 1990-11-10 |
| ATE79763T1 (de) | 1992-09-15 |
| IL94052A (en) | 1995-06-29 |
| AU5310590A (en) | 1990-10-18 |
| EP0392300A1 (de) | 1990-10-17 |
| IL94052A0 (en) | 1991-01-31 |
| HUT54303A (en) | 1991-02-28 |
| US5128126A (en) | 1992-07-07 |
| EP0392300B1 (de) | 1992-08-26 |
| HU902145D0 (en) | 1990-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU206834B (en) | Process for producing pharmaceutical compositions containing interferone and/or tumor necrosis factor for treating systhematically preneoplastic lesions | |
| Farrell et al. | Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality | |
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| DE69821011T3 (de) | Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen | |
| JP2848922B2 (ja) | 胸膜の原発癌を治療する意図の薬剤組成物を製造するためのヒトインターロイキン２の活性を有するポリペプチドの使用 | |
| KR0137361B1 (ko) | Gm-csf를 포함하는 백혈구 기능장애 치료조성물 | |
| US5578571A (en) | Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures | |
| PT87997B (pt) | Processo para a preparacao de composicoes farmaceuticas uteis para a correccao de vias metabolicas aberrantes associadas com ciclos de crescimento descontrolados de celulas tumorais e de virus contendo arn de dupla cadeia | |
| EP0527852B2 (en) | Method and compositions for treating injury | |
| Lewerin et al. | Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy | |
| JP2784401B2 (ja) | 慢性骨髄性白血病の治療方法 | |
| Zaghloul et al. | Interleukin 1 increases thymidine labeling index of normal tissues of mice but not the tumor | |
| US5358709A (en) | Antitumoral composition based on polypeptides having human interleukin 2 activity | |
| JPH0565492B2 (enExample) | ||
| EA015924B1 (ru) | Лечение вич | |
| JPS62289526A (ja) | 組換えヒトαインタ−フェロンによる基底細胞癌の治療 | |
| US20030236189A1 (en) | Two synthetic peptides for treatment and prevention of cancers | |
| JPH0647556B2 (ja) | 病巣内部で組換え型ヒトαインターフェロンを用いる偏平上皮癌の治療 | |
| Nolibe et al. | Stimulation of natural killer cytotoxicity by long-term treatment with double-stranded polynucleotides without induction of hyporesponsiveness | |
| JPH07101877A (ja) | 血小板減少症治療剤 | |
| HU206049B (en) | Process for producing pharmaceutical compositions against primary cancer of pleura and comprising gamma interferon | |
| Alonso et al. | to cyclophosphamide therapy can facilitate tumor growth | |
| JPS62265233A (ja) | インタ−フエロン−β及びインタ−ロイキン−２を含有する医薬組成物 | |
| JPS6287525A (ja) | 新規リンホトキシン含有抗腫瘍剤 | |
| von Wussow | Intralesional Interferon-Alpha-Therapy in Advanced Malignant Melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |